MA33936B1 - Antidotes pour anticoagulants - Google Patents

Antidotes pour anticoagulants

Info

Publication number
MA33936B1
MA33936B1 MA35080A MA35080A MA33936B1 MA 33936 B1 MA33936 B1 MA 33936B1 MA 35080 A MA35080 A MA 35080A MA 35080 A MA35080 A MA 35080A MA 33936 B1 MA33936 B1 MA 33936B1
Authority
MA
Morocco
Prior art keywords
anticoagulants
antidote
antidotes
relates
present
Prior art date
Application number
MA35080A
Other languages
Arabic (ar)
English (en)
Inventor
Ryn Joanne Van
John Edward Park
Norbert Hauel
Ulrich Kunz
Tobias Litzenburger
Keith Canada
Sanjaya Singh
Alisa Waterman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33936(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33936B1 publication Critical patent/MA33936B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules d'anticorps contre des anticoagulants, en particulier le dabigatran, et leur utilisation en tant qu'antidotes de tels anticoagulants.
MA35080A 2010-01-20 2011-01-20 Antidotes pour anticoagulants MA33936B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10151239 2010-01-20
US38391410P 2010-09-17 2010-09-17
PCT/EP2011/050749 WO2011089183A2 (fr) 2010-01-20 2011-01-20 Antidotes d'anticoagulants

Publications (1)

Publication Number Publication Date
MA33936B1 true MA33936B1 (fr) 2013-01-02

Family

ID=42061991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35080A MA33936B1 (fr) 2010-01-20 2011-01-20 Antidotes pour anticoagulants

Country Status (43)

Country Link
US (3) US8486398B2 (fr)
EP (2) EP2525812B1 (fr)
JP (2) JP5575923B2 (fr)
KR (1) KR101781787B1 (fr)
CN (1) CN102711813B (fr)
AP (1) AP2012006242A0 (fr)
AR (1) AR079944A1 (fr)
AU (1) AU2011208719C1 (fr)
BR (1) BR112012018021B1 (fr)
CA (1) CA2787566A1 (fr)
CO (1) CO6571889A2 (fr)
CY (2) CY1118875T1 (fr)
DK (1) DK2525812T3 (fr)
EA (1) EA028371B1 (fr)
EC (1) ECSP12012105A (fr)
ES (1) ES2614992T3 (fr)
FR (1) FR17C1026I2 (fr)
GE (1) GEP20156341B (fr)
HR (1) HRP20170613T1 (fr)
HU (2) HUE032263T2 (fr)
IL (1) IL219427B (fr)
LT (2) LT2525812T (fr)
LU (1) LUC00028I2 (fr)
MA (1) MA33936B1 (fr)
ME (1) ME02602B (fr)
MX (1) MX2012008360A (fr)
MY (1) MY162323A (fr)
NL (1) NL300882I2 (fr)
NO (2) NO2017034I1 (fr)
NZ (1) NZ599508A (fr)
PE (1) PE20121516A1 (fr)
PH (1) PH12012501493A1 (fr)
PL (1) PL2525812T3 (fr)
PT (1) PT2525812T (fr)
RS (1) RS55683B1 (fr)
SG (1) SG182552A1 (fr)
SI (1) SI2525812T1 (fr)
TN (1) TN2012000366A1 (fr)
TW (1) TWI513466B (fr)
UA (1) UA110470C2 (fr)
UY (1) UY33196A (fr)
WO (1) WO2011089183A2 (fr)
ZA (1) ZA201202876B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
CN103619883A (zh) * 2011-01-19 2014-03-05 拜耳知识产权有限责任公司 凝血因子抑制剂的结合蛋白
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
MX349514B (es) 2011-11-29 2017-08-02 Perosphere Inc Agentes de reversion anticoagulante.
HK1215261A1 (zh) 2013-03-14 2016-08-19 Bayer Healthcare Llc 針對與肝素複合的抗凝血酶β的單克隆抗體
JP2016539926A (ja) 2013-10-25 2016-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝血薬の解毒剤
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) * 2014-05-26 2016-01-06 北京九强生物技术股份有限公司 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (fr) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Complexe de thrombine aptamère à utiliser comme antidote à action directe sur les inhibiteurs de la thrombine
JP6776221B2 (ja) * 2014-07-31 2020-10-28 ヘモネティクス・コーポレーションＨａｅｍｏｎｅｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 凝固分析を使用した抗凝固剤の検出および分類
WO2016044645A1 (fr) * 2014-09-17 2016-03-24 Elmaleh David R Dérivés d'anticoagulant pour l'imagerie cardio-vasculaire
JP6581197B2 (ja) 2014-12-31 2019-09-25 深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． 医薬組成物及びその製造方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN111511911B (zh) * 2017-12-24 2023-11-03 诺伊尔免疫生物科技株式会社 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
EP3765505B1 (fr) 2018-03-13 2023-09-27 Tusk Therapeutics Ltd Anticoprs anti cd25 impliquant la déplétion de cellules spécifiques aux tumeurs
JP7407742B2 (ja) 2018-05-11 2024-01-04 ハルシオン セラピューティクス インコーポレイテッド Ｇａｓｐ－１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用
KR102882178B1 (ko) 2018-10-29 2025-11-05 화하이 유에스 인코퍼레이티드 신규한 디펩티드 화합물과 이의 용도
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) * 2021-08-02 2023-06-01 日商諾伊爾免疫生物科技股份有限公司 與scFv等之連接子結合的抗體
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0654085T3 (da) * 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP0672142B1 (fr) 1992-12-04 2001-02-28 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
WO1994029347A1 (fr) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Utilisation de fragments d'anticorps en therapie
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
CA2288994C (fr) 1997-04-30 2011-07-05 Enzon, Inc. Polypeptides a chaine unique modifies par oxyde de polyalkylene
DE19729544A1 (de) * 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
WO2003050531A2 (fr) 2001-12-11 2003-06-19 Algonomics N.V. Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2529819A1 (fr) 2003-06-30 2004-09-23 Domantis Limited Anticorps a domaine unique pegyles
PL3078743T3 (pl) * 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
WO2011023653A1 (fr) 2009-08-24 2011-03-03 Boehringer Ingelheim International Gmbh Interventions d'urgence utilisant du charbon actif en cas de surdosage avec dabigatran étexilate
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
BR112012018021A2 (pt) 2017-06-20
GEP20156341B (en) 2015-08-10
US20120027780A1 (en) 2012-02-02
LUC00028I1 (fr) 2017-07-14
NZ599508A (en) 2014-05-30
KR101781787B1 (ko) 2017-09-26
AP2012006242A0 (en) 2012-04-30
EP3195876A1 (fr) 2017-07-26
CY2017025I1 (el) 2017-11-14
US20150210778A1 (en) 2015-07-30
ME02602B (fr) 2017-06-20
UA110470C2 (ru) 2016-01-12
JP2014210794A (ja) 2014-11-13
ES2614992T3 (es) 2017-06-02
EA201201016A1 (ru) 2013-02-28
CY1118875T1 (el) 2018-01-10
CY2017025I2 (el) 2017-11-14
HUE032263T2 (en) 2017-09-28
SI2525812T1 (sl) 2017-05-31
SG182552A1 (en) 2012-08-30
US8486398B2 (en) 2013-07-16
AU2011208719C1 (en) 2017-07-13
PH12012501493A1 (en) 2012-10-22
EA028371B1 (ru) 2017-11-30
AR079944A1 (es) 2012-02-29
NL300882I2 (nl) 2017-07-20
MY162323A (en) 2017-05-31
HRP20170613T1 (hr) 2017-06-30
PE20121516A1 (es) 2012-11-24
LT2525812T (lt) 2017-02-27
LTC2525812I2 (lt) 2019-05-10
EP2525812A2 (fr) 2012-11-28
FR17C1026I2 (fr) 2018-07-20
IL219427B (en) 2018-05-31
CA2787566A1 (fr) 2011-07-28
EP2525812B1 (fr) 2017-01-18
ZA201202876B (en) 2012-12-27
ECSP12012105A (es) 2012-10-30
HK1173957A1 (en) 2013-05-31
WO2011089183A3 (fr) 2011-11-17
TW201136606A (en) 2011-11-01
US20130289248A1 (en) 2013-10-31
CN102711813A (zh) 2012-10-03
WO2011089183A2 (fr) 2011-07-28
NO2017034I1 (no) 2017-07-11
RS55683B1 (sr) 2017-07-31
MX2012008360A (es) 2012-08-08
IL219427A0 (en) 2012-06-28
DK2525812T3 (en) 2017-02-27
PT2525812T (pt) 2017-04-26
CN102711813B (zh) 2015-03-04
HUS1700030I1 (hu) 2017-08-28
TWI513466B (zh) 2015-12-21
JP2013517317A (ja) 2013-05-16
AU2011208719A1 (en) 2012-05-17
LTPA2017021I1 (lt) 2017-07-25
CO6571889A2 (es) 2012-11-30
US9034822B2 (en) 2015-05-19
TN2012000366A1 (en) 2014-01-30
FR17C1026I1 (fr) 2017-09-08
BR112012018021B1 (pt) 2020-12-08
NO2022036I1 (no) 2022-08-12
PL2525812T3 (pl) 2017-07-31
LUC00028I2 (fr) 2017-09-25
JP5575923B2 (ja) 2014-08-20
UY33196A (es) 2011-08-31
KR20120128126A (ko) 2012-11-26

Similar Documents

Publication Publication Date Title
MA33936B1 (fr) Antidotes pour anticoagulants
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA34488B1 (fr) Composition pesticides
MX374020B (es) Conjugados de polimeros zwiterionicos multifuncionales.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
PH12015500196A1 (en) Methods of treating a tauopathy
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
MA34978B1 (fr) Antidotes pour anticoagulants
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
EA201300514A1 (ru) Разлагаемые волокна
MA37643A1 (fr) Récipients
WO2012156665A3 (fr) Procédés et compositions liés à la sensibilité plaquettaire